Speaker 1: A few years ago and Whisky start a company called
Speaker 1: twenty three and Me. That company provides anyone who uses
Speaker 1: the firm services with information about their own genetic code.
Speaker 1: With that information, people going to determine their own ancestry
Speaker 1: and they can also determine where they have potential genetic
Speaker 1: health problems in the future. I sat down with Anne
Speaker 1: and her home in Palo Alto to discuss the future
Speaker 1: of twenty three and me and how it can help
Speaker 1: solve genetic health care problems. So for those people that
Speaker 1: have not done twenty three and me yet as a
Speaker 1: test kit, tell us what twenty three and me actually is.
Speaker 1: So twenty three and Me is a company that allows
Speaker 1: you to see your own DNA, but it also helps
Speaker 1: you understand what are your genetic health risks? What is
Speaker 1: it that your potentially predisposed to something like type two diabetes,
Speaker 1: h fibrillation. But it also helps you understand your ancestry.
Speaker 1: So where are you from the world, how are you
Speaker 1: connected to other people? And we make it so shoal like.
Speaker 1: One of the big differences with twenty three and Me
Speaker 1: is like we have a it's a social platform, so
Speaker 1: you could share like you and I could share our
Speaker 1: data together, we could potentially be relatives. You can find
Speaker 1: new relatives on twenty three ME and you can also
Speaker 1: share some of your health information. So when people take
Speaker 1: this test, and I should say I took it recently,
Speaker 1: I haven't gotten the results back. I'm nervous about whether
Speaker 1: I'm going to get good or bad results. But all
Speaker 1: you do is you spit into a little tube, you
Speaker 1: mail it back to you, and then how do you
Speaker 1: get out of somebody's saliva all this information? Isn't it?
Speaker 1: It's it's amazing that it's just it's a little tube
Speaker 1: of spit. So you spit in the tube. It actually
Speaker 1: takes about ten minutes to spit um. You have cells
Speaker 1: from your cheek and you know, cells cells that come
Speaker 1: into that spit into the saliva, and you send it
Speaker 1: back to us. We um you know, take part of
Speaker 1: that sample. We extract the DNA and we run it
Speaker 1: on Jean chip. You know, it's a technology that Alumina
Speaker 1: has made and that's part of it's you know, thanks
Speaker 1: to this company. It's a very affordable test. You know,
Speaker 1: it's under two dollars if you want to get the
Speaker 1: health and the ancestry, and it takes a couple of
Speaker 1: weeks for us to turn it around, and then you
Speaker 1: have your genome. And what twenty three really has done
Speaker 1: is built all of the tools, all the interactive software tools,
Speaker 1: so that you can navigate and explore what does the
Speaker 1: genome mean for you? So when you give the results
Speaker 1: back to people, what are they typically most surprised to learn?
Speaker 1: We're first and foremost really concerned about health returning health results,
Speaker 1: and so we spend a lot of time thinking about, Okay,
Speaker 1: if I'm going to tell you your genetically high risk
Speaker 1: for Alzheimer's, how are you going to respond to that? Um,
Speaker 1: We have all kinds of additional layers of consent, We
Speaker 1: have you know, physician videos around it. But I would
Speaker 1: say what the biggest surprises for people is that they
Speaker 1: find out that they have additional family members that they
Speaker 1: did not know about, or the family members that they
Speaker 1: have they did not necessarily you know, they find out
Speaker 1: that they're not necessarily related UM or genetically related. So
Speaker 1: I would say the family connections are frankly actually become
Speaker 1: the biggest surprise for me. UM. I would say, when
Speaker 1: the other biggest questions is like, what is that definition
Speaker 1: of race? So a lot of people find out that
Speaker 1: they have African ancestry or they have Jewish ancestry, but
Speaker 1: they never knew that they had either those. So then
Speaker 1: what really is that definition of being Jewish or what's
Speaker 1: that definition of being African American? With the co discovery
Speaker 1: of DNA with James Watson and uh, he once told
Speaker 1: me that he had his human genome mapped early, one
Speaker 1: of the early people, but he said he didn't want
Speaker 1: to know if he had a predisposition to Alzheimer's, And
Speaker 1: I wonder or a lot of people have that view,
Speaker 1: which is, I'd like to know what my genes would be,
Speaker 1: but don't tell me if I have a predisposition Alzheimer's,
Speaker 1: because not much I can do about it. Is that right?
Speaker 1: I think it's it's actually I would say you have
Speaker 1: sort of two camps, and both camps feel very strongly.
Speaker 1: You have a group of people who very much want
Speaker 1: to know everything about themselves, and they don't necessarily a
Speaker 1: report like Alzheimer's doesn't necessarily have clinical utility in the
Speaker 1: capacity that you're going to have a treatment or you're
Speaker 1: going to change anything, but it has high personal utility,
Speaker 1: meaning that those people might decide they create a will
Speaker 1: they retire earlier or one of the main things that
Speaker 1: we see people do is they go and they buy
Speaker 1: long term care insurance. So what we see is that
Speaker 1: they take a personal utility and they're actually proactive with
Speaker 1: that information. Now, in the consumer world, what people like
Speaker 1: is repeat customers. And so if I did as I
Speaker 1: just did, I took a twenty three and me test.
Speaker 1: Once I get the results, how do you monetize me
Speaker 1: in the future? What are there are different things you
Speaker 1: can sell to me? Or because that's what usually companies
Speaker 1: like to do is go back to their customers and
Speaker 1: sell them something else. So what do you have interesting?
Speaker 1: You know, I could look back like if we if
Speaker 1: I ever do a retrospective on twenty three and me,
Speaker 1: was it a mistake to not have a subscription product earlier?
Speaker 1: So we do today have a subscription product. In early
Speaker 1: early stages of the subscription product, the original I ideas
Speaker 1: with twenty three me was that we'd get you in
Speaker 1: in the simplest way possible because we didn't want to
Speaker 1: overly confuse the messaging about a subscription or not. But
Speaker 1: it was just it was so unknown, like why do
Speaker 1: you even want your genetic information. So the idea was
Speaker 1: like I needed to see the market just with like
Speaker 1: my early adopters is like, just like what is this information?
Speaker 1: And make it as simple as possible. But what I've
Speaker 1: seen over the last sixteen years is that my customers
Speaker 1: are really engaged. So for example, over eighty five of
Speaker 1: our customers are consenting for research, like really high numbers
Speaker 1: of people opt into research. Over fift of my customers
Speaker 1: are coming back on a quarterly basis. So if I
Speaker 1: subscribe to one of your subscription services and I have
Speaker 1: a predisposition to disease A or be, you're likely to
Speaker 1: send me information on that from time and time. Is
Speaker 1: that what you mean? We'll potentially update that report or
Speaker 1: well potentially said you additional But the main thing we
Speaker 1: did we recently acquired a company called Lemonade Health. And
Speaker 1: the reason why we acquired Lemonade Health was two folds,
Speaker 1: like mostly to fit answer the question that you just asked.
Speaker 1: Here is like you find out your higher risk, Well,
Speaker 1: now what can you do? So first and foremost will
Speaker 1: be able to have medical protocols about how can we
Speaker 1: actually deliver genomic based care. No one has adopted genomic medicine,
Speaker 1: So how can I adopt genomic based care in a
Speaker 1: primary care setting to really help think about how do
Speaker 1: I engage, Like how do I help you be healthy? So,
Speaker 1: first and foremost we're going to like solve that question
Speaker 1: for you. Second is really about the engagement side. You
Speaker 1: find out your higher risk for heart disease, well, like
Speaker 1: an article just came out about caffeine consumption in heart
Speaker 1: disease or sleep in heart disease, I want you to
Speaker 1: update me. So the company then will start to update
Speaker 1: people to say, hey, here's the latest about what's happening.
Speaker 1: Here's things that are in your hands that you should
Speaker 1: actually start to go and think about. Now, you have
Speaker 1: a fairly distinguished family. I'd like to talk about it
Speaker 1: for a moment. It's been written about. I recall your
Speaker 1: father was a physics professor in the head of the
Speaker 1: physics department at Stanford. Your mother is a distinguished educator
Speaker 1: and wrote a book about how to raise distinguished, accomplished children.
Speaker 1: She sure did. One of your sisters is an epidemiologist
Speaker 1: at the University of California, professor. Another sister runs YouTube.
Speaker 1: And then you are the founder of twenty three and
Speaker 1: so what was it like growing up on the Stanford
Speaker 1: campus with all this talented around you. I think the
Speaker 1: best thing about how we grew up is we were
Speaker 1: surrounded by an academic culture of people who really prioritized
Speaker 1: education and learning, but also really encourage people to pursue
Speaker 1: their passions. So what I what I love about all
Speaker 1: my sisters, Like we both you know, Susan and I
Speaker 1: happened to be in higher profile roles, but everyone is
Speaker 1: pursuing something that they really love and they really enjoy doing.
Speaker 1: So I think that the best thing we all got
Speaker 1: from our parents was to pursue your passions, no matter
Speaker 1: how esoteric, or whether or not they're monetize able or
Speaker 1: if it's you know, an academic kind of pursuit. Right.
Speaker 1: So I grew up in the Stanford campus. I assume
Speaker 1: you're an all A student. Your sisters are all a's.
Speaker 1: So where did you want to go to school? In college?
Speaker 1: You know, I kind of debate. I mean, my my
Speaker 1: father went to Harvard. Like the realities, you know, things
Speaker 1: based on your parents, and my father was really lucky.
Speaker 1: He went to Harvard after he came from he came
Speaker 1: from Poland. He was in school and he went early
Speaker 1: to Harvard. Um My mom went to Berkeley, so I knew.
Speaker 1: My parents always encouraged me. They would say, you know, go,
Speaker 1: like it's important to go, it's important to have education,
Speaker 1: it's important to go to a good school. But there's
Speaker 1: a lot of good schools, and I would say today
Speaker 1: people over emphasized, like you know what, exactly what school
Speaker 1: I have to go to. There's so many great schools,
Speaker 1: and frankly, the great school finds you. Um So, I
Speaker 1: always wanted to go. I thought Harvard would be fascinating.
Speaker 1: My oldest sister she went to Harvard. Um I used
Speaker 1: to stay with her at Harvard. I just like I
Speaker 1: was fascinated by people who wore tweed and had leather patches.
Speaker 1: Um So I decided not to end up going to Harvard.
Speaker 1: I went to Yale for on weekend, and I fell
Speaker 1: in love with Yale and I'm a yalely I just
Speaker 1: loved it. Okay, And what did you study there? I
Speaker 1: studied biology. And did you want to go to medical school?
Speaker 1: I did. I thought about going to medical school. I
Speaker 1: loved research, but I wasn't Um I can't say that
Speaker 1: I was an incredibly talented researcher. I would say that
Speaker 1: detail in that precision. There was a lot of wonderful
Speaker 1: post docs in the lab who helped me get through
Speaker 1: my research. But I love the science. I love molecular biology,
Speaker 1: like it keeps me up at night that you have
Speaker 1: this incredible set of processes going on right now in
Speaker 1: your body. She went to Yale, you graduated. He decided
Speaker 1: not going to go to medical school. But what did
Speaker 1: you do? Well? I and I actually always you know,
Speaker 1: and I joke a lot. I'm on the Kaiser Permanent,
Speaker 1: a school medicine board, and I sometimes joke. I was like,
Speaker 1: at some point, I'll still go to medical school, like I,
Speaker 1: I mean, it's like the most it's the most interesting
Speaker 1: job you can have, I think, But um, but I
Speaker 1: decided not to, and very randomly I got a job.
Speaker 1: I randomly got my resume sent to the Wallenberg family
Speaker 1: in Sweden and they offered me a job. I didn't
Speaker 1: know who they were, I didn't know what it was,
Speaker 1: um and but I thought it was interesting, like it
Speaker 1: was like a one year opportunity paid me forty dollars.
Speaker 1: I thought I would never make that much money again,
Speaker 1: so I figured I would go and do it for
Speaker 1: a year. So where did you do this? So? I
Speaker 1: worked in New York for almost ten years. Um. So
Speaker 1: I started off with the Wallenberg's and then I went
Speaker 1: to a series of hedge funds afterwards. Right so, um,
Speaker 1: nothing could be higher in life than working for hedge funds. Right? No,
Speaker 1: exactly how did you feel there was a higher calling
Speaker 1: than working for a hedge fund at the point I
Speaker 1: was my my my best friend's father used to call
Speaker 1: me a leech on society. Um so, and I took
Speaker 1: up fondly. I was like, look, the reality for me
Speaker 1: is I was learning, Um, there was no better education
Speaker 1: about it was like getting a PC. Like I went
Speaker 1: to medical meetings every week. I went, I was speaking
Speaker 1: with experts every day, Like I knew the health care
Speaker 1: system so well. But I did feel after ten years,
Speaker 1: I was investing in a system that was fundamentally not
Speaker 1: really like not really the system that I wanted to
Speaker 1: be part of. And um, and then I wanted to
Speaker 1: do something. I feel like, you can't. If you're going
Speaker 1: to complain about a problem, then you should, you know,
Speaker 1: figure out how to fix it. So what year did
Speaker 1: you decide to start? Twenty three? And me, it started
Speaker 1: thinking about a lot in two thousand five, and then
Speaker 1: it was two thousand two six that we actually started.
Speaker 1: So for people who haven't paid attention to the genome world,
Speaker 1: in the year two thousand, I think it was the
Speaker 1: federal government said that two researchers, Francis Collins working at
Speaker 1: n I H and Craig Ventor, who has had a
Speaker 1: private company, had basically discovered the human genome. So that happened,
Speaker 1: and I think two thousand President Clinton said that was
Speaker 1: a tie, and they both given credit for it, leaving
Speaker 1: aside the intramural fighting that had gone on before. So
Speaker 1: it was then thought, Okay, the world is gonna be
Speaker 1: so much better now that we know that human genome.
Speaker 1: It's been mapped. There will be no more to Jesus,
Speaker 1: we can fix all diseases. But what happened for the
Speaker 1: ten years or so or fifteen years afterwards, it didn't
Speaker 1: seem like much happened. But this is that's such an
Speaker 1: interesting question, um, and this is also something that plagues me.
Speaker 1: Like Francis Collins and President Clinton at the time came
Speaker 1: out and said this human genome, like sequencing, the human
Speaker 1: genome is going to transform how we diagnose treat and
Speaker 1: prevent all human disease. So it's a huge statement about
Speaker 1: what's going to happen. And I would argue one of
Speaker 1: the biggest issues that's happened today is there has not
Speaker 1: been adoption of genetic technology. And I would say point
Speaker 1: back to again part of my dissatisfaction with the investing
Speaker 1: world is part of the reason why it has not
Speaker 1: been adopted is that a lot of genetic information is
Speaker 1: about prevention. So for instance, if I tell you are
Speaker 1: likely to have an adverse event from this this antidepressant,
Speaker 1: or your potentially higher risk for atrial fib those are
Speaker 1: not well monetized medical events. You can make a lot
Speaker 1: of money treating atro fibrillation, but you cannot make money
Speaker 1: in the absence of a disease. So, for instance, if
Speaker 1: I successfully keep you healthy to a hundred, you are
Speaker 1: not a profit center for the healthcare world. And so
Speaker 1: genetic information a lot of that potential is not really
Speaker 1: adopted in the primary care setting, in part because there's
Speaker 1: not an assilium monetization path. So you're starting to see
Speaker 1: that more in cancer, you start to see it more
Speaker 1: in pregnancy related but it has not been widely adopted
Speaker 1: I would say the second thing is that the US
Speaker 1: is far far behind countries like the UK. So the
Speaker 1: UK has an incredibly impressive program called the uk Biobank
Speaker 1: where they have half a million people who have consented,
Speaker 1: who are participating in a nationwide program and it's amazing,
Speaker 1: like everyone including twenty three me uses the data that
Speaker 1: comes out from the UK Biobank. The US has totally
Speaker 1: fallen behind. So we have a program called all of
Speaker 1: Us where we're trying to get people. It's supposed to
Speaker 1: be a million people, but the UK has already left
Speaker 1: prog us and said we have a five million person program.
Speaker 1: Now that's going to be, you know, running ahead. So
Speaker 1: the US and part there's also been a lot of
Speaker 1: politics around you know, how is this going to execute?
Speaker 1: You know, what are the ethics on it? If we
Speaker 1: want to really capture the benefit of the human genome,
Speaker 1: you need a massive I would say multiple countries that
Speaker 1: come together and have like a hundred million people who
Speaker 1: come together so you can really understand what the code is.
Speaker 1: The US is obsessed not so much with the UK,
Speaker 1: but it's with China. So it is China ahead of
Speaker 1: us in this area or not? Well, China is crushing
Speaker 1: us too, but we don't know as much about what
Speaker 1: they're actually doing. So I would say, like the one
Speaker 1: big worry that I always have is like China. China
Speaker 1: knows how to execute and they know how to lead
Speaker 1: on a program in China has made no um, no
Speaker 1: uncertain statements about their interest in genetics and that they
Speaker 1: want to be the world leader in this next the
Speaker 1: genetic revolution. So China has made huge efforts. They have
Speaker 1: huge programs, and they also have something called the Beijing
Speaker 1: Genome Institute, which is an incredibly well funded you know, um,
Speaker 1: you know, well funded with the government and a massive
Speaker 1: sequencing shop where tons and tons of discoveries are being
Speaker 1: made and there's nothing in the U s or nothing
Speaker 1: in the UK that's even comparable. As you look at
Speaker 1: the company you've created, and you look at what you've
Speaker 1: done with your life, how do you think you're having
Speaker 1: an impact on the world for the betterment of the world.
Speaker 1: I think in two ways. So one, I personally believe
Speaker 1: there's no more interesting challenge than trying to understand the
Speaker 1: code of life. And I think that twenty three is
Speaker 1: frankly the best positioned entity public or not not public
Speaker 1: or you know, for profit or nonprofit, we are by
Speaker 1: far and away the best positioned entity to solve the
Speaker 1: question as to what does the human genome mean and
Speaker 1: how can you apply it to individuals? So one, I
Speaker 1: think we are going to be the lead in deciphering
Speaker 1: the human genetic code. Second, I transform people's lives, like
Speaker 1: it's what keeps me up at night, and it's also
Speaker 1: what keeps me going. I tell someone that they're higher
Speaker 1: risk for breast cancer and that leads them to get amasectomy,
Speaker 1: and I can potentially prevent an early death, like that's amazing.
Speaker 1: Or I can reconnect to family members where they've been
Speaker 1: lost for years. Like. One thing twenty three ME does
Speaker 1: is that we generate incredibly meaningful information for individuals. By
Speaker 1: the way, all my twenty three and ME tasks I'm
Speaker 1: waiting for they get the results soon. How can I
Speaker 1: be certain that nobody will know the results other than me?
Speaker 1: How can I be sure that you're not selling the
Speaker 1: data to somebody else? So we honor the fact that, like,
Speaker 1: this is your genome and you should do with it
Speaker 1: what you want. So that means, though I'm not going
Speaker 1: to prevent you from sharing it, I'm going to give
Speaker 1: you options. So we as we ask you, do you
Speaker 1: want to opt into research and over our customers are
Speaker 1: now opting in so but it's not a default. We
Speaker 1: actually ask you like you have to elect that option.
Speaker 1: If you wanted to share your genetic information with me,
Speaker 1: you have that opportunity. But there's no defaults, like nothing
Speaker 1: is mandatory. So it's all about you being in control.
Speaker 1: So your company went public not too long ago through
Speaker 1: a spac process. I think it was a spact that
Speaker 1: was involved with Richard Branson and Virgin So any regrets
Speaker 1: to backgoing public or throw us back? No, I mean
Speaker 1: it's interesting because it's it's definitely not you know, the
Speaker 1: most positive of market times. Um, but I loved I
Speaker 1: love the process, like being being public. The process of
Speaker 1: going public is a lot of work. And so when
Speaker 1: we decided about or we at least looked at opportunities
Speaker 1: to go public, Like one of the big considerations for
Speaker 1: me was how much time is it going to take
Speaker 1: from me? And I wanted, like, I'm very much focused
Speaker 1: and very much of a CEO that like I like
Speaker 1: to operate and I like to be in the weed,
Speaker 1: like how are we executing? So I wanted to make
Speaker 1: sure I was minimizing times, like how much time is
Speaker 1: it going to take for the whole process? This back
Speaker 1: process is incredibly efficient. Um. I got incredibly lucky with
Speaker 1: Richard Branson. He's a very high quality investor. He has
Speaker 1: an incredibly educated team. He's actually invested in healthcare before.
Speaker 1: He's run you know, benefits companies. He's had a care
Speaker 1: company in the UK, so he knows this space and
Speaker 1: he was specifically looking at healthcare in a consumer space.
Speaker 1: So I'm happy with the like the process was smooth
Speaker 1: and we ended up in a really successful situation. But
Speaker 1: many tech companies have seen their prices go down, so
Speaker 1: you you have as well? I said, so does that
Speaker 1: bother you and you're saying, well, we'll come back, or
Speaker 1: what is your view generally on the the future of
Speaker 1: tech companies in terms of the valuations they once had.
Speaker 1: I think coming from Wall Street has given me a
Speaker 1: good perspective on this. You know, Wall Street is not
Speaker 1: always a reflective of true value. And I can also
Speaker 1: say that there's like no shortage of opportunities that people
Speaker 1: have missed where there's a diamond in the gem like
Speaker 1: you know, or diamond the rough where I could look
Speaker 1: at like the early days of Google, or I could
Speaker 1: look at the early days of Amazon, where people did
Speaker 1: not really understand the story, and I would put us
Speaker 1: in that bucket. A lot of people don't quite understand
Speaker 1: what we do. They either think are we ancestry. We
Speaker 1: also have a biotech side, which we haven't even talked about,
Speaker 1: is like how do you translate all this data into
Speaker 1: drug discovery? So we're complicated story. The market conditions are bad.
Speaker 1: You know, markets are efficient over time, You're largely seen
Speaker 1: as a consumer company, and consumer companies have relatively lower
Speaker 1: pe multiples tech companies and biotech companies when the market
Speaker 1: comes back and higher multiple. So can you transform your
Speaker 1: company into being a tech or biotech company by working
Speaker 1: on disease solutions as opposed to just giving people their information?
Speaker 1: We are, Um, that's actually one of the beauties. So
Speaker 1: twenty three AM when we started the company, remember I said,
Speaker 1: it was like all about like exploring the genome. And
Speaker 1: so one of the things we do is we have
Speaker 1: this huge research arm like how can I help best
Speaker 1: understand what the human genome means? And that's part of
Speaker 1: the whole process from the very beginning, is how do
Speaker 1: I consent people for research, engage them in research, learn
Speaker 1: about them, and then I have a whole analytics team
Speaker 1: and data science team that's in looking at all that
Speaker 1: data to see how do I translate it either as
Speaker 1: a consumer product back to you or actually now for
Speaker 1: research and discovery. So I have over a hundred people
Speaker 1: in a twenty three therapeutics arm of the business. We
Speaker 1: have a major collaboration with GSK. We have over fifty
Speaker 1: programs that are in development and we have to actually
Speaker 1: in clinical trials, So we're a hundred Like absolutely, thinking
Speaker 1: about how people will benefit from the human genome is
Speaker 1: about actually translating that information into theory. And GSK is
Speaker 1: a very large healthcare company medical research company. What are
Speaker 1: you doing specifically with him? Specifically it's on target identification,
Speaker 1: So we're specifically working with g s K to look
Speaker 1: at the data that twenty three is generated to see
Speaker 1: can we identify new novel drug targets. So you've built
Speaker 1: a successful company, but you might not want to run
Speaker 1: in for the next ten years, or do you? And
Speaker 1: if you didn't, would you want to go into government?
Speaker 1: At the president called you to serve our country? Would
Speaker 1: you go into government or would you start another company.
Speaker 1: I love what I do and I feel like I
Speaker 1: have this luxury with twenty three ME that um, it's
Speaker 1: and it keeps evolving. You know, we started out just
Speaker 1: as a you know, started out a consumer company. We're
Speaker 1: thick in research, we got into drug discovering two fifteen,
Speaker 1: and now we're getting to the delivery of care. So
Speaker 1: I've been really lucky with twenty three me that it's
Speaker 1: been endlessly interesting and I'm surrounded by incredibly talented, brilliant
Speaker 1: individuals where I learned from them, and what I always
Speaker 1: advised people to do is like you should keep you
Speaker 1: should take jobs where you're learning, and if you stop
Speaker 1: learning in a job, then you should quit. And like frankly,
Speaker 1: when people leave twenty three me, like I say, if
Speaker 1: you're not learning anymore, you should move on. So I'm
Speaker 1: I'm hun on committed to twenty three. That said, my
Speaker 1: other passion is other direct to consumers, Like I want
Speaker 1: to build out a true consumer empowered healthcare world, like
Speaker 1: one that is outside of the existing system. And I
Speaker 1: do there's no greater force than government and the opportunity
Speaker 1: for government, So you know, there's always ideas, like I
Speaker 1: could always do a sabbatical. You have three talented sisters too,
Speaker 1: very um accomplished parents. Your parents ever said, well, guess
Speaker 1: what your sister just did to kind of say you
Speaker 1: should work even harder and be more, even more accomplished.
Speaker 1: They put rivalries together, or you don't have that problem. No,
Speaker 1: they know my parents. My parents are lovely, and my
Speaker 1: sisters are you know, my sisters are quick to you know,
Speaker 1: make me humble. I mean, it's part of why I
Speaker 1: lived with my sisters. Like I had somebody over today,
Speaker 1: like I had we had a coffee chat that with
Speaker 1: somebody in the company today who you know? We auction
Speaker 1: this off. And my sister was laughing. She's like someone
Speaker 1: paid money to eat with you. And I was like thanks,
Speaker 1: Like that wasn't the kinds of reminders I get from
Speaker 1: the family. So your mother wrote this book about raising
Speaker 1: talented children. Do you raise your children the way she
Speaker 1: raised you? I listen. I think each generation improves upon
Speaker 1: the last generation. So I think that we have taken um.
Speaker 1: I have I haven't. I couldn't read the whole book.
Speaker 1: I read parts of the book, but I wrote part
Speaker 1: of I wrote the forward UM, and my my take
Speaker 1: on that was more to like give the reality, like
Speaker 1: the perspective from the child, Like I know my mother
Speaker 1: is telling you about how she raised us, but let
Speaker 1: me tell you about my mother, and so I look,
Speaker 1: I think it's it's my mom. My parents are incredible,
Speaker 1: Like I'm really grateful and there's lots of things that
Speaker 1: I learned from them, but I'm definitely not adopting everything
Speaker 1: they did. If your children go to Harvard and rather
Speaker 1: than yeah, we'll be okay, let's not talk about that.
Speaker 1: I mean my kids, my kids. I want my kids
Speaker 1: to My kids are so interesting and so different, you know,
Speaker 1: I want them to be passionate. That's the only thing
Speaker 1: I care about is I want them to wake up
Speaker 1: every day and say, like, I love what I'm doing.
Speaker 1: And you would you be upset if they went into
Speaker 1: something important like private equity? Are you giving me the
Speaker 1: job offer? Thanks for listening to hear more of my interviews.
Speaker 1: You can subscribe and download my podcast on Spotify, Apple,
Speaker 1: or wherever you listen